Form 4: IDEAYA Biosciences Exec Boosts Stake, Receives Options

IDEAYA Biosciences' SVP of Finance and Investor Relations, Andres Ruiz Briseno, increased his common stock holdings and received a significant stock option grant.

Summary

• Andres Ruiz Briseno, SVP, Head of Finance and Investor Relations at IDEAYA Biosciences, Inc. (IDYA), acquired 682 shares of common stock at $23.256 per share on November 29, 2024, through the Employee Stock Purchase Plan.
• An additional 1,253 shares of common stock were acquired by Mr. Briseno at $16.9065 per share on November 28, 2025, also via the Employee Stock Purchase Plan.
• Mr. Briseno was granted 80,000 stock options with an exercise price of $32.19 per share on January 30, 2026.
• The stock options vest 25% on January 1, 2027 (the first anniversary of the January 1, 2026 Vesting Commencement Date), and then 1/48th of the total shares vest monthly thereafter, achieving full vesting on January 1, 2030.
• Following these transactions, Mr. Briseno beneficially owns 26,466 shares of common stock and 80,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. Insider accumulation and a significant option grant suggest executive confidence in IDEAYA Biosciences' future, although the ESPP purchases are routine and the option grant is part of compensation.

Positives

• A key executive, the SVP of Finance and Investor Relations, increased his direct ownership in the company through the Employee Stock Purchase Plan, signaling confidence.
• The grant of 80,000 stock options to a senior executive aligns management's long-term interests with shareholder value creation, as the options vest over four years.

Future Outlook

The stock option grant includes a four-year vesting schedule, with 25% vesting on the first anniversary of January 1, 2026, and the remainder vesting monthly thereafter, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that insider purchases, even through an ESPP, and significant option grants to senior finance executives are generally viewed positively by the market. Such actions can signal management's belief in the company's future prospects and align executive incentives with long-term shareholder value, particularly in the biotechnology sector where long development cycles are common.

Stakeholder Impact

• Shareholders may interpret the insider stock acquisitions and option grant as a positive sign of management's belief in the company's future performance and commitment to long-term value creation.

Next Steps

• The stock options will begin vesting on January 1, 2027, with full vesting expected by January 1, 2030.

Key Dates

Recommendation

The insider's decision to increase common stock holdings, even through an ESPP, combined with a substantial long-term option grant, suggests a strong belief in the company's future. This insider confidence, particularly from the Head of Finance, can be a positive indicator for investors, warranting a 'buy' recommendation.

Keywords

IDEAYA Biosciences, IDYA, Insider Trading, Form 4, Stock Options, Employee Stock Purchase Plan, Executive Compensation, Beneficial Ownership, Biotechnology